PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.Company Information
- Company Name
- PROVECTUS BIOPHARMACEUTICALS, INC.
- CIK
- CIK0000315545
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PVCT: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PVCT
SEC filing data through
Insider Sentiment
- Last purchase
- 2017-12-14
- Last sale
- —
- Shares purchased (TTM)
- 200,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 129,812
- Shares outstanding
- 420,279,879
- Ownership
- 0.03%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 7.14%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Current | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Receivables Net Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Deferred Revenue Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Other Accrued Liabilities Current | 3 | 4 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 8 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 8 | 9 | 9 | 9 | ||||||
| Interest Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Notes Payable To Bank Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 1 | 1 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Notes Payable | - | - | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities | 8 | 7 | 7 | 7 | 7 | 6 | 7 | 6 | 8 | 9 | 9 | 9 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 258 | 257 | 256 | 255 | 254 | 253 | 251 | 249 | 246 | 245 | 245 | 244 | ||||||
| Stockholders Equity | -6 | -7 | -6 | -6 | -6 | -5 | -6 | -5 | -8 | -7 | -8 | -8 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -265 | -264 | -263 | -262 | -260 | -259 | -257 | -255 | -254 | -253 | -253 | -252 | ||||||
| Minority Interest | -0 | -0 | -0 | -0 | -0 | 0 | -0 | - | - | - | - | - | ||||||
| Liabilities And Stockholders Equity | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | - | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||||
| Common Stock Shares Issued | 420 | 420 | 420 | 420 | 420 | - | 420 | 420 | 420 | 420 | 420 | 420 | ||||||
| Shares Outstanding | 420 | 420 | 420 | 420 | 420 | - | 420 | 420 | 420 | 420 | 420 | 420 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) — SEC Financial Statements & Analysis
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) is a pharmaceutical preparations company, incorporated in DE. PROVECTUS BIOPHARMACEUTICALS, INC. trades on OTC as: PVCT. PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, PROVECTUS BIOPHARMACEUTICALS, INC. carries a market cap of $29.00M, a P/E ratio of -6.01x, a P/B ratio of -4.61x, a P/S ratio of 372.90x, an enterprise value of $27.84M, and an EV/EBITDA multiple of -6.08x. On profitability, it posts an operating margin of -9472.39%, a net margin of -9839.02%, a Return on Equity (ROE) of 79.32%, and a Return on Assets (ROA) of -439.33%. Per share, it reports EPS of $-0.01, diluted EPS of $-0.01, free cash flow per share of $-0.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -23.87% year-over-year, and EPS growth of -23.87% year-over-year. On the balance sheet, it maintains a current ratio of 0.18x, a quick ratio of 0.15x, working capital of $-6.34M, a debt-to-equity ratio of -1.23x, a debt ratio of 5.27, an interest coverage ratio of -23.06x, free cash flow of $-2.43M (TTM), and net debt of $-1.16M. Figures sourced from SEC EDGAR.
- Market Cap
- $29.00M
- P/E TTM
- -6.01x
- EPS TTM
- $-0.01
- P/B TTM
- -4.61x
- ROE TTM
- 79.32%
- ROA TTM
- -439.33%
- Debt To Equity
- -1.23x
- Free Cash Flow TTM
- $-2.43M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is PROVECTUS BIOPHARMACEUTICALS, INC. in?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) operates in the Pharmaceutical Preparations industry.
What exchange does PVCT trade on?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) trades on the OTC.
Where is PROVECTUS BIOPHARMACEUTICALS, INC. incorporated?
PROVECTUS BIOPHARMACEUTICALS, INC. is incorporated in DE.
When was PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s most recent SEC filing?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is PVCT's market cap?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) has a market capitalization of $29.00M as of 2026-06-30.
What is PVCT's EPS (earnings per share)?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s trailing twelve month EPS is $-0.01 as of 2026-06-30.
What is PVCT's ROE (return on equity)?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s trailing twelve month Return on Equity (ROE) is 79.32% as of 2026-06-30.
What is PVCT's ROA (return on assets)?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s trailing twelve month Return on Assets (ROA) is -439.33% as of 2026-06-30.
What is PVCT's EV/EBITDA?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s trailing twelve month EV/EBITDA is -6.08x as of 2026-06-30.